Investors, It's Time for Quadruple Profit Gains, AGAIN... in Biotech Stocks
Companies /
Sector Analysis
Jul 05, 2011 - 07:46 AM GMT
By: DailyWealth
Dr. Steve Sjuggerud writes: Is it time for quadruple-digit gains in biotech stocks, again?
I think it just might be...
Let me explain why today... and show you how you can get in on it.
A quick look back over history shows that when biotech stocks finally take off, they can go absolutely nuts...
Back in the dot-com days, biotech stocks as a group soared 457% in 18 months.
I don't mean that one or two biotech stocks went up nearly 500% in "about" 18 months – I'm not cherry-picking winners or exact dates. I mean the entire Nasdaq Biotechnology Index rose 457% from the end of August 1998 to the end of February 2000.
You might think that was a one-time thing... But the truth is, in the early 1990s, biotech stocks soared even more... with a 1,000%-plus move. (That was in the Datastream Biotech Index. Nasdaq's index didn't exist yet).
With numbers like those, you can see why I often say...
If you catch just one biotech bull market in your lifetime, you may never have to work again.
Biotech stocks have actually had four massive, triple-digit bull markets since the 1980s. But today, the Nasdaq Biotech Index is lower than it was back in March 2000. We're due for a bull market in biotech.
Back in those previous bull markets, we didn't have a simple investment that would rise even more than the index. But now we do... the ProShares Ultra Nasdaq Biotech fund (BIB). It's a "double long" fund on the Nasdaq Biotech Index. For every 1% the index rises, BIB should go up 2%.
This fund is only a couple years old. But thanks to our True Wealth Systems databases, we were able to essentially replicate the performance of a double-long index going all the way back to 1983... The performance of BIB shouldn't be too different than the performance of this hypothetical double-long index. Take a look:
As you can see, this double-long biotech index had two quadruple-digit bull markets... around 1990 and around 2000. Now that we're in 2011, it seems like we're overdue for another triple-digit run, at least.
In True Wealth Systems, we've built a simple trend-following strategy to capture the gains in biotech stocks. When the line in the chart above is "green," we're in "buy" mode.
Our simple strategy has compounded gains at 46% a year when in buy mode, versus next-to-nothing when you're not in buy mode.
Right now, it's in buy mode.
Remember... "If you catch just one biotech bull market in your lifetime, you may never have to work again."
This could be the one. Get on board – through BIB – if you're not on board already. Use a trailing stop, to protect your downside risk if I'm wrong. Otherwise, enjoy the ride...
Once the great bull market finally arrives, it could be the greatest trade you ever make.
Good investing,
Steve
http://www.dailywealth.com
The DailyWealth Investment Philosophy: In a nutshell, my investment philosophy is this: Buy things of extraordinary value at a time when nobody else wants them. Then sell when people are willing to pay any price. You see, at DailyWealth, we believe most investors take way too much risk. Our mission is to show you how to avoid risky investments, and how to avoid what the average investor is doing. I believe that you can make a lot of money – and do it safely – by simply doing the opposite of what is most popular.
Customer Service: 1-888-261-2693 – Copyright 2011 Stansberry & Associates Investment Research. All Rights Reserved. Protected by copyright laws of the United States and international treaties. This e-letter may only be used pursuant to the subscription agreement and any reproduction, copying, or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of Stansberry & Associates Investment Research, LLC. 1217 Saint Paul Street, Baltimore MD 21202
Disclaimer: The above is a matter of opinion provided for general information purposes only and is not intended as investment advice. Information and analysis above are derived from sources and utilising methods believed to be reliable, but we cannot accept responsibility for any losses you may incur as a result of this analysis. Individuals should consult with their personal financial advisors.
© 2005-2022 http://www.MarketOracle.co.uk - The Market Oracle is a FREE Daily Financial Markets Analysis & Forecasting online publication.
